Alizapride
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Alizapride.svg | |
| Alizapride
| |
| Systematic (IUPAC) name | |
| N-[(1-allylpyrrolidin-2-yl)methyl]-6-methoxy- 1H-benzotriazole-5-carboxamide | |
| Identifiers | |
| CAS number | |
| ATC code | A03 |
| PubChem | |
| Chemical data | |
| Formula | C16H21N5O2 |
| Mol. mass | 315.37 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, intramuscular, intravenous |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide.[1]
Alizapride is marketed under various trade names including Plitican, Superan and Vergentan.[2]
References
- ↑ Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol 22 (4): 316–20. PMID 3048762.
- ↑ (French) Alizapride Chlorhydrate. BIAM (June 2 1997). Retrieved on 2007-08-14.
Drugs for functional gastrointestinal disorders (A03) | |
|---|---|
| Drugs for functional bowel disorders | antimuscarinics: Mebeverine - Dicycloverine - Propantheline
papaverine and derivatives: Papaverine - Drotaverine - Moxaverine acting on serotonin receptors: 5-HT3 antagonists (Alosetron, Cilansetron) - 5HT4 agonists (Mosapride, Tegaserod) other: Diisopromine - Isometheptene - Phloroglucinol - Proglumide - Tridihexethyl |
| Belladonna and derivatives (antimuscarinics) | Atropine - Hyoscyamine - Butylscopolamine - Methylscopolamine |
| Propulsives | primarily dopamine antagonists (Metoclopramide/Bromopride, Domperidone, Alizapride) - serotonin agonists (Cisapride) - Clebopride |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
